Nitrazepam

From Self-sufficiency
Jump to: navigation, search
Nitrazepam
150px
150px
Systematic (IUPAC) name
9-nitro- 6-phenyl- 2,5-diazabicyclo [5.4.0] undeca- 5,8,10,12- tetraen- 3-one
Clinical data
Pregnancy
category
  • AU: D
  • US: D (Evidence of risk)
Routes of
administration		 Oral
Legal status
Legal status
Pharmacokinetic data
Bioavailability 53-94%
Metabolism Hepatic
Biological half-life 16-38 hours
Excretion Renal
Identifiers
CAS Number 146-22-5
ATC code N05CD02 (WHO)
PubChem CID 4506
DrugBank none
ChemSpider 4350
Chemical data
Formula C15H11N3O3
Molar mass 281.3 g/mol[[Script error: No such module "String".]]
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.
File:Image047.jpg
Alodorm bottle containing 25 tablets of 5mg Nitrazepam

Nitrazepam is a type of benzodiazepine drug and is marketed in English-speaking countries under the following brand names: Alodorm, Arem, Insoma, Mogadon, Nitrados, Nitrazadon, Ormodon, Paxadorm, Remnos and Somnite.[1] It is a hypnotic drug used in the treatment of insomnia which has sedative and motor impairing properties,[2] as well as anxiolytic, amnestic, anticonvulsant and skeletal muscle relaxant properties. Nitrazepam is available in 5 mg and 10 mg tablets. In the Netherlands, Australia, Israel and the United Kingdom it is only available in 5 mg tablets. In Denmark it is available as 2.5 mg and 5 mg tablets under the name Pacisyn.

Tolerance to the sleep inducing effects of nitrazepam occurs after about 7 days;[3][4] tolerance also frequently occurs to the anticonvulsant effects of nitrazepam.[5][6] A benzodiazepine dependence can develop with a benzodiazepine withdrawal syndrome occurring when the drug is stopped or the dose lowered.[7] Common withdrawal symptoms include; anxiety, insomnia, concentration problems and fatigue.[8] Long-term effects of benzodiazepines such as nitrazepam include worsening mental and physical health as well as cognitive deficits;[9][10] immunological disturbances[11] and an increased risk of developing cancer has also been associated with long-term use.[12]

Nitrazepam at doses of 5 mg or higher impairs driving skills[13] and nitrazepam, like other hypnotic drugs is associated with an increased risk of road traffic accidents.[14] In the elderly nitrazepam is associated with an increased risk of falls and hip fractures due to impairments on body balance.[15] The elimination half life of nitrazepam is 40 hours in the elderly and 29 hours in younger adults.[16][17] Nitrazepam is commonly taken in overdose by drug abusers or suicidal individuals, sometimes leading to death.[18][19][20] Nitrazepam is teratogenic if taken in overdose during pregnancy with 30 percent of births showing congenital abnormalities.[21] Nitrazepam is a popular drug of abuse in countries where it is available.[22][23][24]

Nitrazepam is not recommended during pregnancy as it is associated with causing a neonatal withdrawal syndrome[25] and is not generally recommended in alcohol- or drug-dependent individuals as well as people with comorbid psychiatric disorders.[26] The Dutch, British and French system called the System of Objectified Judgement Analysis for assessing whether drugs should be included in drug formularies based on clinical efficacy, adverse effects, pharmacokinetic properties, toxicity and drug interactions was used to assess nitrazepam. A Dutch analysis using the system found that nitrazepam is unsuitable to be included in drug prescribing formularies.[27]

Therapeutic uses

Nitrazepam is used to treat short-term sleeping problems (insomnia),[28] namely difficulty falling asleep, frequent awakening, early awakenings or a combination of each.

Nitrazepam is sometimes used for refractory epilepsies. However, long term prophylactic treatment of epilepsy has considerable drawbacks. Most importantly the loss of antiepileptic effects due to tolerance which renders prolonged nitrazepam therapy ineffective. Nitrazepam also has the drawback of significant side effects such as sedation, which is why nitrazepam and benzodiazepines in general are only prescribed in the acute management of epilepsies.[29] Nitrazepam has been found to be more effective than clonazepam in the treatment of West syndrome which is an age dependent epilepsy, affecting the very young. However, as with other epilepsies treated with benzodiazepines, long term therapy becomes ineffective with prolonged therapy and the side effects of hypotonia and drowsiness are troublesome with nitrazepam therapy, other antiepileptic agents are therefore recommended for long term therapy, possibly Corticotropin (ACTH) or vigabatrin.[30] In uncontrolled studies nitrazepam has shown effectiveness in infantile spasms; nitrazepam is sometimes considered as a treatment option for this indication when other drugs fail to control infantile spasms.[31]

Utilisation

Nitrazepam along with diazepam, oxazepam and temazepam in 1993 represented 82% of the benzodiazepine market in Australia.[32] The rate of benzodiazepine prescribing in Tasmania is higher than in other Australian states; Nitrazepam and flunitrazepam prescribing levels in Tasmania are disturbingly high.[33] Prescribing of hypnotics in Norway is quite restrictive with only 4 hypnotics which are prescribable; nitrazepam, flunitrazepam, zolpidem and zopiclone.[34] The usage of benzodiazepine hypnotics in local authority homes for the elderly 1982 in Edinburgh, established via a clinical survey, was that 34% of residents were taking sleeping medication. However, the number varied between the homes, with some homes reporting only 2.3% of residents to be on hypnotic medication and others up to 56.5% on hypnotic drugs. Nitrazepam was the most frequently prescribed hypnotic medication accounting for a third of hypnotic use in Edinburgh residential homes in 1982.[35]

Side effects

Common side effects

Central nervous system depression including, somnolence, dizziness, depressed mood, rage, violence, fatigue, ataxia, headache, vertigo, impairment of memory, impairment of motor functions, hangover feeling in the morning, slurred speech, decreased physical performance, numbed emotions, reduced alertness, muscle weakness, double vision and inattention have been reported. Unpleasant dreams and rebound insomnia has also been reported. High levels of confusion, clumsiness also occurs after administration of nitrazepam.[36] Increased reaction time, co-ordination problems and impaired learning and memory.[37]

Impaired learning and memory occurs due to the action of the drug on benzodiazepine receptors which causes a dysfunction in the cholinergic neuronal system.[38] Nitrazepam causes a reduced output of serotonin which is closely involved in regulating mood and may be the cause of feelings of depression in users of nitrazepam or other benzodiazepines.[39]

Nitrazepam is a long acting benzodiazepine with an elimination half life of 15-38 (mean elimination half life 26 hours).[1] Residual 'hangover' effects after nighttime administration of nitrazepam such as sleepiness, impaired psychomotor and cognitive functions may persist into the next day which may impair the ability of users to drive safely and increases the risk of falls and hip fractures.[40] Significant impairment of visual perception and sedative effects persisting into the next day typically occurs with nitrazepam administration as was demonstrated in a human clinical trial assessing the effect of nitrazepam on peak saccade velocity.[41]

Impairment of psychomotor function may especially occur after repeated administration, with the elderly being more vulnerable to this adverse effect.[42] Overall accuracy of completing tasks is impaired after repeated administration of nitrazepam and is due to drug accumulation of nitrazepam. The elderly are more vulnerable to these side effects.[43]

Less common side effects

Hypotension,[44] faintness, palpitation, rash or pruritus, gastrointestinal disturbances, changes in libido. Very infrequently, paradoxical reactions may occur, e.g. excitement, stimulation, hallucinations, hyperactivity and insomnia. Also depressed or increased dreaming, disorientation, severe sedation, retrograde amnesia, headache, hypothermia, delirium tremens.[45] Acroparaesthesia has been reported as a side effect from nitrazepam with symptoms including, pins and needles in hands and loss of power of fingers and clumsiness of the fingers.[46] Severe liver toxicity has also been reported.[47]

Tolerance dependence and withdrawal

Tolerance

Tolerance to a drug's effects occurs after regular exposure to a drug. The mechanism of nitrazepam tolerance may be due to down-regulation of benzodiazepine receptors (observed in rats).[48] When tolerance and habituation occurs to nitrazepam its pharmacokinetic profile changes with absorption of the drug slowing down, elimination increasing and brain concentration of nitrazepam increasing significantly.[49] Increased levels of GABA in cerebral tissue and alterations in the activity state of the serotoninergic system occurs as a result of nitrazepam tolerance.[50]

After six days of use, tolerance to nitrazepam's but not temazepam's sleep-inducing effects and performance-impairing effects occurred in a study.[3] One study demonstrated tolerance to the sleep promoting effects of nitrazepam and temazepam after 7 days nightly administration in 19 elderly inpatients. Self reported quality of sleep was found to be increased after the first nights administration of either nitrazepam or temazepam but by day 7 self reported quality of sleep was found to have returned to baseline in these patients, suggesting the development of tolerance after 7 days use. The effect was more pronounced in patients of lower intelligence.[4] In mice tolerance to the anticonvulsant properties of nitrazepam developed profoundly and rapidly over 6 days, and then did not proceed. Some anticonvulsant effects were still apparent after 6 days administration.[51] In humans tolerance to the anticonvulsant effects of nitrazepam is a frequent occurrence.[5][6]

Dependence and withdrawal

See also: benzodiazepine withdrawal syndrome

Benzodiazepine drugs such as nitrazepam can cause dependence and addiction and is what is known as the benzodiazepine withdrawal syndrome. Withdrawal from nitrazepam or other benzodiazepines often leads to withdrawal symptoms which are similar to those seen with alcohol and barbiturates, including delirium tremens.[52][53] The higher the dose and the longer the drug is taken the greater the risk of experiencing unpleasant withdrawal symptoms. Withdrawal symptoms can however occur at standard dosages and also after short term treatment. Benzodiazepine treatment should be discontinued as soon as possible via a slow and gradual dose reduction regime.[54] Common withdrawal symptoms include, anxiety, insomnia, concentration problems and fatigue.[8]

Frequent use of nitrazepam may cause dependence and when the drug is reduced or stopped, withdrawal symptoms occur. Withdrawal symptoms including a worsening of insomnia compared to baseline typically occurs after discontinuation of nitrazepam even after short term single nightly dose therapy.[55] Dependence on benzodiazepines such as nitrazepam or temazepam often occurs due to discharging patients from hospital on benzodiazepines who were started on benzodiazepine hypnotics in hospital. It is recommended that hypnotic use in hospital be limited to 5 days to avoid the development of drug dependence and withdrawal insomnia.[7]

After discontinuation of nitrazepam a rebound effect may occur about 4 days after stopping medication.[56] Nitrazepam has more side effects than other hypnotic drugs and tolerance to sedative properties and rebound insomnia after discontinuation occurs after only 7 days administration.[57] Tolerance to the anticonvulsant and anxiolytic effects also develops rapidly during daily administration.[58]

Abrupt withdrawal after long term use from therapeutic doses of nitrazepam may result in a severe benzodiazepine withdrawal syndrome. Reports in the medical literature report of two psychotic states developing after abrupt withdrawal from nitrazepam including delirium after abrupt withdrawal of 10 mg of nitrazepam and in another case auditory hallucinations and visual cognitive disorder developed after abrupt withdrawal from 5 mg of nitrazepam and 0.5 mg of triazolam. Gradual and careful reduction of the dosage was recommended to prevent severe withdrawal syndromes from developing.[59] Antipsychotics increase the severity of benzodiazepine withdrawal effects with an increase in the intensity and severity of convulsions.[60] Depersonalisation has also been reported as a benzodiazepine withdrawal effect from nitrazepam.[61]

Special precautions

Benzodiazepines require special precaution if used in the alcohol- or drug-dependent individuals and individuals with comorbid psychiatric disorders.[26] It has been recommended that caution should be exercised in prescribing nitrazepam to anyone who is of working age due to the significant impairment of psychomotor skills; This impairment is greater the higher the dosage that is prescribed.[62] Nitrazepam in doses of 5 mg or more causes significant deterioration in vigilance performance combined with increased feelings of sleepiness.[63] Doses as low as 5 mg of nitrazepam can impair driving skills.[13] Therefore people driving or conducting activities which require vigilance should exercise caution in using nitrazepam or possibly avoid it all together.[64]

Elderly

Nitrazepam, similar to other benzodiazepines and nonbenzodiazepines causes impairments in body balance and standing steadiness in individuals who wake up at night or the next morning. Falls and hip fractures are frequently reported. The combination with alcohol increases these impairments. Partial, but incomplete tolerance develops to these impairments.[15] Nitrazepam has been found to be dangerous in elderly patients due to a significant increased risk of falls.[65] This increased risk is probably due to the persisting drug effects of nitrazepam well into the next day.[66] Nitrazepam is a particularly unsuitable hypnotic for the elderly as it induces a disability characterised by general mental deterioration, inability to walk, incontinence, dysarthric, confusion, prone to stumbling, falls and disoriention which can occur from doses as low as 5 mg. The nitrazepam induced symptomatology can lead to a misdiagnosis of brain disease in the elderly e.g. dementia and can also lead to the symptoms of postural hypotension which may also get misdiagnosed. It was reported that a geriatric unit was seeing as many as 7 patients a month with nitrazepam induced disabilities and health problems. It was recommended that nitrazepam should join the barbiturates in not being prescribed to the elderly.[67] Only nitrazepam and lorazepam were found to increase the risk of falls and fractures in the elderly.[68] CNS depression occurs much more frequently in the elderly and is especially common in doses above 5 mg of nitrazepam.[69] Both young and old patients report sleeping better after 3 nights use of nitrazepam however they also report feeling less awake and are slower on psychomotor testing up to 36 hours after intake of nitrazepam. The elderly showed cognitive deficits, making significantly more mistakes in psychomotor testing than younger patients despite similar plasma levels of the drug, suggesting that the elderly are more sensitive to nitrazepam due to increased sensitivity of the aging brain to nitrazepam. Confusion and disorientation can result from chronic nitrazepam administration to elderly subjects. Also the effects of a single dose of nitrazepam may last up to 60 hours after administration.[70]

Children

Nitrazepam is not recommended for use in those under 18. Use in very young children may be especially dangerous. Children treated with nitrazepam for epilepsies may develop tolerance within months of continued use, with dose escalation often occurring with prolonged use. Sleepiness, deterioration in motor skills and ataxia were common side effects in children with tuberous sclerosis treated with nitrazepam. The side effects of nitrazepam may impair the development of motor and cognitive skills in children treated with nitrazepam. Withdrawal of nitrazepam only occasionally resulted in a return of seizures and some children withdrawn from nitrazepam appeared to improve. Development, e.g. able to walk at 5 years was impaired in many children taking nitrazepam but was not impaired with several other non benzodiazepine antiepileptic agents. It has been recommended that children being treated with nitrazepam should be reviewed and have their nitrazepam gradually discontinued whenever appropriate.[6] Excess sedation, hypersalivation, swallowing difficulty, high incidence of aspiration pneumonia as well as several deaths has been associated with nitrazepam therapy in children.[31]

Pregnancy

The use of nitrazepam during pregnancy can lead to intoxication of the new born. A neonatal withdrawal syndrome can also occur if nitrazepam or other benzodiazepines are used during pregnancy with symptoms such as hyper-excitability, tremor and gastro-intestinal upset (diarrhea or vomiting) occurring. Breast feeding by mothers using nitrazepam is not recommended.[71] Nitrazepam is a long acting benzodiazepine and there is a risk of drug accumulation, even though no active metabolites are formed during metabolism. Accumulation can occur in various body organs including the heart, accumulation is even greater in babies. Nitrazepam rapidly crosses the placenta and also is present in breast milk in high quantities. Therefore benzodiazepines including nitrazepam should be avoided during pregnancy.[72] In early pregnancy nitrazepam levels are lower in the baby than in the mother and in the later stages of pregnancy nitrazepam is found in equal levels in both the mother and the unborn child.[73] Internationally benzodiazepines are known to cause harm when used during pregnancy and nitrazepam is a category D drug during pregnancy.

Benzodiazepines are lipophilic and rapidly penetrate membranes and therefore rapidly penetrate the placenta with significant uptake of the drug. Use of benzodiazepines e.g. nitrazepam in late pregnancy especially high doses may result in floppy infant syndrome.[74] Use in the third trimester stage of pregnancy may result in the development of a severe benzodiazepine withdrawal syndrome in the neonate. Withdrawal symptoms from benzodiazepines in the neonate may include hypotonia, and reluctance to suck, to apnoeic spells, cyanosis, and impaired metabolic responses to cold stress. These symptoms may persist for hours or months after birth.[25]

Other precautions

Caution in hypotension.

Caution in those suffering from hypotension, nitrazepam may worsen hypotension.[44]

Caution in hypothyroidism.

Caution should be exercised by people who have hypothyroidism as this condition may cause a long delay in the metabolism of nitrazepam leading to significant drug accumulation.[75]

Contraindications

Nitrazepam should be avoided in patients with chronic obstructive pulmonary disease (COPD), especially during acute exacerbations of COPD, because serious respiratory depression may occur in patients who are receiving hypnotics.[76]

As with other hypnotic drugs nitrazepam is associated with an increased risk of road traffic accidents.[14] Nitrazepam is recommended to be avoided in patients who drive or operate machinery. A study assessing driving skills of sedative hypnotic users found that users of nitrazepam were found to be significantly impaired up to 17 hours after dosing, whereas users of temazepam did not show significant impairments of driving ability. These results reflect the long acting nature of nitrazepam.[77]

Toxicity

Humans

The Journal of Clinical Sleep Medicine published a paper which had carried out a systematic review of the medical literature concerning insomnia medications and raised concerns about benzodiazepine receptor agonist drugs, the benzodiazepines and the Z-drugs that are used as hypnotics in humans. The review found that almost all trials of sleep disorders and drugs are sponsored by the pharmaceutical industry. It was found that the odds ratio for finding results favorable to industry in industry-sponsored trials was 3.6 times higher than non-industry-sponsored studies and that 24% of authors did not disclose being funded by the drug companies in their published paper when they were funded by the drug companies. The paper found that there is little research into hypnotics that is independent from the drug manufacturers. Also of concern was the lack of focus in industry sponsored trials on their own results showing that use of hypnotics is correlated with depression. The author was concerned that there is no discussion of adverse effects of benzodiazepine agonist hypnotics discussed in the medical literature such as significant increased levels of infection, cancers and increased mortality in trials of hypnotic drugs and an overemphasis on the positive effects. No hypnotic manufacturer has yet tried to refute the epidemiology data that shows that use of their product is correlated with excess mortality. The author stated that "major hypnotic trials is needed to more carefully study potential adverse effects of hypnotics such as daytime impairment, infection, cancer, and death and the resultant balance of benefits and risks." The author concluded that more independent research into daytime impairment, infection, cancer, and shortening of lives of sedative hypnotic users is needed to find the true balance of benefits and risks of benzodiazepine agonist hypnotic drugs in the treatment of insomnia.[12] Chronic use of benzodiazepines seemed to cause significant immunological disorders in a study of selected outpatients attending a psychopharmacology department.[11]

Cancer

Benzodiazepine usage for more than 1 – 6 months at prescribed doses is associated with an increased risk of the development of ovarian cancer.[78] There have been 15 epidemiologic studies which have shown that hypnotic drug use is associated with increased mortality, mainly due to increased cancer deaths in humans. The cancers included cancer of the brain, lung, bowel, breast, and bladder, and other neoplasms. Not only are benzodiazepines associated with an increased risk of cancer, the benzodiazepine receptor agonist Z-drugs also are associated with cancer in humans in these studies. Initially U.S. Food and Drug Administration (FDA) reviewers did not want to approve the Z drugs due to concerns of cancer but ultimately changed their mind and approved the drugs despite the concerns. The data shows that trial subjects receiving hypnotic drugs had an increased the risk of developing cancer. The review author concluded saying; "the likelihood of cancer causation is sufficiently strong now that physicians and patients should be warned that hypnotics possibly place patients at higher risk for cancer".[79]

Mortality

Nitrazepam therapy compared with other drug therapies increases risk of death when used for intractable epilepsy in an analysis of 302 patients. The risk of death from nitrazepam therapy may be greater in younger patients (children below 3.4 years in the study) with intractable epilepsy. In older children (above 3.4 years) the tendency appears to be reversed in this study.[80] Nitrazepam may cause sudden death in children. Nitrazepam therapy can cause swallowing incoordination, high-peaked esophageal peristalsis, bronchospasm, delayed cricopharyngeal relaxation and severe respiratory distress necessitating ventilatory support in children. Nitrazepam may promote the development of parasympathetic overactivity or vagotonia leading to potentially fatal respiratory distress in children.[81]

Liver

Nitrazepam has been associated with severe hepatic disorders, similar to other nitrobenzodiazepines. Nitrobenzodiazepines such as nitrazepam, nimetazepam, flunitrazepam and clonazepam are more toxic to the liver than other benzodiazepines as they are metabolically activated by CYP3A4 which can result in cytotoxicity. This activation can lead to the generation of free radicals, oxidation of thiol as well as covalent binding with endogenous macromolecules; this results then in oxidation of cellular components or inhibition of normal cellular function. Metabolism of a non-toxic drug to reactive metabolites is has been connected with causing a variety of adverse reactions.[47]

Long-term effects

Long-term effects of benzodiazepine drugs such as nitrazepam include worsening mental and physical health as well as cognitive deficits. These adverse effects show improvement after a period of abstinence.[9][10]

Interactions

Nitrazepam interacts with the antibiotic erythromycin which is a strong inhibitor of CYP3A4, which affects concentration peak time. This interaction is not to believed to be clinically important.[82] However, anxiety, tremor and depression have been documented in a case report following administration of nitrazepam and triazolam. Following administration of erythromycin to the patient, repetitive hallucinations and abnormal bodily sensations developed. The patient had however acute pneumonia and renal failure. Co-administration of benzodiazepine drugs at therapeutic doses with erythromycin may cause serious psychotic symptoms especially in those with other significant physical complications.[83] Oral contraceptive pills, reduce the clearance of nitrazepam which may lead to increased plasma levels of nitrazepam and accumulation.[84] Rifampin increases the clearance of nitrazepam significantly and probenecid decreases the clearance of nitrazepam significantly.[85] Cimetidine slows down the elimination rate of nitrazepam leading to more prolonged effects of nitrazepam and increased risk of accumulation.[86] Alcohol (ethanol) in combination with nitrazepam may cause a synergistic enhancement of the hypotensive properties of both benzodiazepines and alcohol.[87] Benzodiazepines including nitrazepam may inhibit the glucuronidation of morphine leading to increased levels of and prolongation of the effects of morphine in rat experiments.[88]

Pharmacology

Nitrazepam is a nitrobenzodiazepine.[89][90] It is a 1,4 benzodiazepine, with the chemical name 1,3-Dihydro-7-nitro-5-phenyl-2H-1,4- benzodiazepin-2-one.

It is long acting, is lipophilic and is metabolised hepatically via oxidative pathways. It acts on benzodiazepine receptors in the brain which are associated with the GABA receptors, causing an enhanced binding of GABA (gamma-aminobutyric acid) to GABAA receptors.[91] GABA is a major inhibitory neurotransmitter in the brain, involved in inducing sleepiness, muscular relaxation and control of anxiety and seizures, and slows down the central nervous system. The mechanism of action of nitrazepam is the same as other benzodiazepine drugs and zopiclone.[92] The anticonvulsant properties of nitrazepam and other benzodiazepines may be in part or entirely due to binding to voltage-dependent sodium channels rather than benzodiazepine receptors. Sustained repetitive firing seems to be limited by benzodiazepines effect of slowing recovery of sodium channels from inactivation in mouse spinal cord cell cultures.[93] The muscle relaxant properties of nitrazepam are produced via inhibition of polysynaptic pathways in the spinal cord of decerebrate cats.[94] It is a full agonist of the benzodiazepine receptor.[95] The endogenous opioid system may play a role in some of the pharmacological properties of nitrazepam in rats.[96] Nitrazepam causes a decrease in the cerebral contents of the amino acids glycine and alanine in the mouse brain. The decrease may be due to activation of benzodiazepine receptors.[97] At high doses decreases in histamine turnover occur as a result of nitrazepam's action at the benzodiazepine-GABA receptor complex in mouse brain.[98] Nitrazepam has demonstrated cortisol suppressing properties in man.[99] Nitrazepam is an agonist for both central benzodiazepine receptors, and to the peripheral type benzodiazepine receptors found in rat neuroblastoma cells.[100]

EEG and sleep

In sleep laboratory studies, nitrazepam decreased sleep onset latency. In psychogeriatric in-patients nitrazepam was found to be no more effective than placebo tablets in increasing total time spent asleep, was found to significantly impair trial subjects abilities to move and carry out everyday activities the next day and it was concluded that nitrazepam should not be used as a sleep aid in psychogeriatric in-patients.[101]

Stage 2 NREM sleep is significantly increased by nitrazepam but SWS stage sleep is significantly decreased by nitrazepam.[102] There is delay in the onset, and decrease in the duration of REM sleep. Following discontinuation of the drug, REM sleep rebound has been reported in some studies.[103] Nitrazepam is reported to significantly affect stages of sleep: a decrease stage 1, 3 and 4 sleep and to increase stage 2.[104] In young volunteers the pharmacological properties of nitrazepam was found to produce sedation, impaired psychomotor performance and standing steadiness. EEG tests showed a decrease of alpha activity and increased the beta activity. These effects increased according to blood plasma levels of nitrazepam.[105] Performance was significantly impaired 13 hours after dosing with nitrazepam as was decision-making skills. EEG tests show more drowsiness and light sleep 18 hours after nitrazepam intake more so than amylobarbitone. Fast activity was recorded via EEG 18 hours after nitrazepam dosing.[106] An animal study demonstrated that nitrazepam induces a drowsy pattern of spontaneous EEG including high-voltage slow waves and spindle bursts increase in the cortex and amygdala, while the hippocampal theta rhythm is desynchronized. Also low-voltage fast waves occur particularly in the cortical EEG. The EEG arousal response to auditory stimulation and to electric stimulation of the mesencephalic reticular formation, posterior hypothalamus and centromedian thalamus is significantly suppressed. The photic driving response elicited by a flash light in the visual cortex is also suppressed by nitrazepam. Estazolam was found to be more potent however.[107] Nitrazepam increases the slow wave light sleep (SWLS) in a dose-dependent manner whilst suppressing deep sleep stages. Less time is spent in stages 3 and 4 which are the deep sleep stages, when benzodiazepines such as nitrazepam are used. Benzodiazepines are therefore not good hypnotics in the treatment of insomnia. The suppression of deep sleep stages by benzodiazepines may be especially problematic to the elderly as they naturally spend less time in the deep sleep stage.[108]

Pharmacokinetics

Nitrazepam is largely bound to plasma proteins.[109] Benzodiazepines such as nitrazepam are lipid soluble and have a high cerebral uptake.[110] The time for nitrazepam to reach peak plasma concentrations following oral administration is about 2 hours (0.5 to 5 hours). The half life of nitrazepam is 16.5 to 48.3 (mean 28.8) hours. Both low dose (5 mg) and high dose (10 mg) of nitrazepam significantly increases growth hormone levels in humans.[111] Nitrazepam's half life in the cerebrospinal fluid, 68 hours, indicates that nitrazepam is eliminated extremely slowly from the cerebrospinal fluid.[112] Nitrazepam has a half life of about 29 hours in young people and a much longer half life in the elderly. In the elderly the half life is about 40 hours.[16][17] Concomitant food intake has no influence on the rate of absorption of nitrazepam nor on its bioavailability. Therefore nitrazepam can be taken with or without food.[113]

Abuse potential

See also: Benzodiazepine drug misuse

Nitrazepam is a drug which is very frequently involved in drug intoxication.[114] Nitrazepam was the most commonly detected benzodiazepine in urine samples in the UK in 1997 suggesting a high liking and preference amongst drug abusers. However, it has been superseded by temazepam, despite the fact that temazepam is much more highly regulated in the UK. Temazepam is Class B drug, while nitrazepam is a Class C drug.[22][23] In Nepal, nitrazepam is a major drug of abuse as is codeine, heroin, buprenorphine and cannabis.[24]

Nitrazepam in animal studies has been shown to increase reward seeking which may suggest increased risk of addictive behavioural patterns.[115] A study found that nitrazepam caused significant euphoria as against placebos and was identified as an active drug by freshly detoxified experienced drug abusers of heroin and other drugs. Nitrazepam resembled diazepam (Valium), however, on certain parameters the effects produced by nitrazepam were more pronounced in these drug abusers. Nitrazepam was found to be an abusable drug and has similar abuse liability like diazepam, if not slightly higher in these drug abusers. Nitrazepam in drug abusers produces effects including feeling energetic, relaxed, drunken, talkative, pleasure and euphoria. In India up to 50-60% of heroin addicts abuse benzodiazepines and 20% of injecting substance misusers also inject benzodiazepines.[116]

Treatment with nitrazepam should usually not exceed 7 to 10 consecutive days. Use for more than 2 to 3 consecutive weeks requires complete re-evaluation of the patient. Prescriptions for nitrazepam should be written for short-term use (7 to 10 days) and it should not be prescribed in quantities exceeding a 1-month supply. Dependence can occur in as little as four weeks.[117]

Benzodiazepines, including diazepam, nitrazepam and flunitrazepam account for the largest volume of forged drug prescriptions in Sweden, a total of 52% of drug forgeries being for benzodiazepines, suggesting benzodiazepines are a major prescription drug class of abuse.[118] In Bangladesh, benzodiazepines, including nitrazepam, are used in organised crime to commit drug facilitated crime such as robbery.[119]

Nitrazepam and other benzodiazepines are detected frequently in cases of people suspected of driving under the influence of drugs in Sweden. Other benzodiazepines and zolpidem and zopiclone are also found in high numbers in suspected impaired drivers. Many drivers have blood levels far exceeding the therapeutic dose range suggesting a high degree of abuse potential for benzodiazepines and zolpidem and zopiclone.[120] In Northern Ireland in cases where drugs were found in tests on impaired drivers, benzodiazepines were found to be present in 87% of cases.[121][122] In Norway benzodiazepines are the most commonly detected illicit drug in suspected drugged drivers being detected in 38-57 percent of drivers.[123]

Overdose

Nitrazepam overdose may result in stereotypical symptoms of benzodiazepine overdose including intoxication, impaired balance and slurred speech. In cases of severe overdose this may progress to a comatose state with the possibility of death. The risk of nitrazepam overdose is increased significantly if nitrazepam is abused in conjunction with opioids, as was highlighted in a review of deaths of users of the opioid buprenorphine.[124] Nitrobenzodiazepines such as nitrazepam can result in a severe neurological effects.[125] Nitrazepam taken in overdose is associated with a high level of congenital abnormalities (30 percent of births). Most of the congentital abnormalities were mild deformaties.[21]

Severe nitrazepam overdose resulting in coma causes the central somatosensory conduction time (CCT) after median nerve stimulation to be prolonged and the N20 to be dispersed. Brain-stem auditory evoked potentials demonstrate delayed interpeak latencies (IPLs) I-III, III-V and I-V. Toxic overdoses therefore of nitrazepam cause prolonged CCT and IPLs. An alpha pattern coma can be a feature of nitrazepam overdose with alpha patterns being most prominent in the frontal and central regions of the brain.[126][127]

Benzodiazepines were implicated in 39% of suicides by drug poisoning in Sweden, with nitrazepam and flunitrazepam accounting for 90% of benzodiazepine implicated suicides, in the elderly over a period of 2 decades. In three quarters of cases death was due to drowning, typically in the bath. Benzodiazepines were the predominant drug class in suicides in this review of Swedish death certificates. In 72% of the cases benzodiazepines were the only drug consumed. Benzodiazepines and in particular nitrazepam and flunitrazepam should therefore be prescribed with caution in the elderly.[20] In a brain sample of a fatal nitrazepam poisoning high concentrations of nitrazepam and its metabolite were found in the brain of the deceased person.[128]

In a retrospective study of deaths, when benzodiazepines were implicated in the deaths, the benzodiazepines nitrazepam and flunitrazepam were the most common benzodiazepines involved. Benzodiazepines were a factor in all deaths related to drug addiction in this study of causes of deaths. Nitrazepam and flunitrazepam were significantly more commonly implicated in suicide related deaths than natural deaths. In four of the cases benzodiazepines alone were the only cause of death.[18] In Australia, nitrazepam and temazepam were the benzodiazepines most commonly detected in overdose drug related deaths. In a third of cases benzodiazepines were the sole cause of death.[19]

Individuals with chronic illnesses are much more vulnerable to lethal overdose with nitrazepam, as fatal overdoses can occur at relatively low doses in these individuals.[129]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

Benzodiazepine derivatives (N05BA, N05CD)
1,4-Benzodiazepines

Bromazepam · Camazepam · Carburazepam · Chlordiazepoxide · Cinolazepam · Clonazepam · Clorazepate · Cyprazepam · Delorazepam · Demoxepam · Devazepide* · Diazepam · Doxefazepam · Elfazepam · Ethyl carfluzepate · Ethyl dirazepate · Ethyl loflazepate · Fletazepam · Fludiazepam · Flunitrazepam · Flurazepam · Flutemazepam · Flutoprazepam · Fosazepam · Gidazepam · Halazepam · Iclazepam · Ketazolam · Lorazepam · Lormetazepam · Meclonazepam · Medazepam · Menitrazepam · Metaclazepam · Motrazepam · Nimetazepam · Nitrazepam · Nitrazepate · Nordazepam · Nortetrazepam · Oxazepam · Phenazepam · Pinazepam · Pivoxazepam · Prazepam · Proflazepam · Quazepam · QH-II-66 · Reclazepam · Ro5-2904 · Sulazepam · Temazepam · Tetrazepam · Tifluadom* · Tolufazepam · Tuclazepam · Uldazepam

1,5-Benzodiazepines
2,3-Benzodiazepines *
Triazolobenzodiazepines
Imidazobenzodiazepines
Oxazolobenzodiazepines
Thienodiazepines
Pyridodiazepines
Pyrazolodiazepines
Pyrrolodiazepines
Tetrahydroisoquinobenzodiazepines
Benzodiazepine prodrugs
 * atypical activity profile (not GABAA receptor ligands)
GABAA receptor agonist
Other GABA agents
Carbonic anhydrase inhibitor
Channel blockers
Primarily sodium
Primarily calcium
Unknown/ungrouped
Indirect GABA agents
Unknown/multiple/
unsorted
GABAA receptor
Ultrashort-acting
Short/intermediate-
acting
Long-acting
Ungrouped
Short-acting
Intermediate-acting
Long-acting
Flurazepam • Flutoprazepam • Nitrazepam • Quazepam
Dialkylphenols
Alpha-2 adrenergic
receptor
Melatonin receptor
Histamine receptor &
Acetylcholine receptor
5-HT2A &
α1-adrenergic
Selective 5-HT2A & α1-adrenergic antagonists
GABAB receptor /
GHB receptor
GHB Type
Orexin receptors
Orexin antagonists
Other receptors/
ungrouped
Other

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)

cs:Nitrazepam

de:Nitrazepam fa:نیترازپام fr:Nitrazépam it:Nitrazepam hu:Nitrazepám ja:ニトラゼパム no:Nitrazepam pl:Nitrazepam ru:Нитразепам sl:Nitrazepam fi:Nitratsepaami sv:Nitrazepam

tr:Nitrazepam
  1. ↑ "Benzodiazepine Names". non-benzodiazepines.org.uk. Retrieved 2008-12-29. 
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. ↑ 3.0 3.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  4. ↑ 4.0 4.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  5. ↑ 5.0 5.1 Loiseau P (1983). "[Benzodiazepines in the treatment of epilepsy]". Encephale. 9 (4 Suppl 2): 287B–292B. PMID 6373234. 
  6. ↑ 6.0 6.1 6.2 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  7. ↑ 7.0 7.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  8. ↑ 8.0 8.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  9. ↑ 9.0 9.1 Ashton H (2005). "The diagnosis and management of benzodiazepine dependence" (PDF). Curr Opin Psychiatry. 18 (3): 249–55. doi:10.1097/01.yco.0000165594.60434.84. PMID 16639148. 
  10. ↑ 10.0 10.1 Ashton H (2004). "Benzodiazepine dependence". In Haddad P, Dursun S, Deakin B (eds.). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. Oxford University Press. pp. 239–60. ISBN 978-0198527480. 
  11. ↑ 11.0 11.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  12. ↑ 12.0 12.1 Kripke DF (December 15, 2007). "Who should sponsor sleep disorders pharmaceutical trials?". J Clin Sleep Med. 3 (7): 671–3. PMC 2556906 Freely accessible. PMID 18198797. major hypnotic trials is needed to more carefully study potential adverse effects of hypnotics such as daytime impairment, infection, cancer, and death and the resultant balance of benefits and risks. 
  13. ↑ 13.0 13.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  14. ↑ 14.0 14.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  15. ↑ 15.0 15.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  16. ↑ 16.0 16.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  17. ↑ 17.0 17.1 Vozeh S (November 21, 1981). "[Pharmacokinetic of benzodiazepines in old age]". Schweiz Med Wochenschr. 111 (47): 1789–93. PMID 6118950. 
  18. ↑ 18.0 18.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  19. ↑ 19.0 19.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  20. ↑ 20.0 20.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  21. ↑ 21.0 21.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  22. ↑ 22.0 22.1 Professor C Heather Ashton (2002). "BENZODIAZEPINE ABUSE". Drugs and Dependence. Harwood Academic Publishers. Retrieved September 25, 2007. 
  23. ↑ 23.0 23.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  24. ↑ 24.0 24.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  25. ↑ 25.0 25.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  26. ↑ 26.0 26.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  27. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  28. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  29. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  30. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  31. ↑ 31.0 31.1 Tsao, CY. (May 20, 2009). "Current trends in the treatment of infantile spasms" (PDF). Neuropsychiatr Dis Treat. 5: 289–99. PMC 2695218 Freely accessible. PMID 19557123. 
  32. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  33. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  34. ↑ Kayed K (March 30, 1995). "[Insomnia and hypnotics]". Tidsskr nor Laegeforen. 115 (9): 1087–90. PMID 7725291. 
  35. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  36. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  37. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  38. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  39. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  40. ↑ Vermeeren A (2004). "Residual effects of hypnotics: epidemiology and clinical implications". CNS Drugs. 18 (5): 297–328. doi:10.2165/00023210-200418050-00003. PMID 15089115. 
  41. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  42. ↑ Morgan K (1985). "Effects of repeated dose nitrazepam and lormetazepam on psychomotor performance in the elderly". Psychopharmacology (Berl). 86 (1-2): 209–11. doi:10.1007/BF00431711. PMID 3927357. 
  43. ↑ Morgan K (1984). "Effects of two benzodiazepines on the speed and accuracy of perceptual-motor performance in the elderly". Psychopharmacology Suppl. 1: 79–83. PMID 6147843. 
  44. ↑ 44.0 44.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  45. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  46. ↑ MacLean H (February 24, 1973). "Nitrazepam: another interesting syndrome" (pdf). Br Med J. 1 (5851): 488. doi:10.1136/bmj.1.71.488. 
  47. ↑ 47.0 47.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  48. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  49. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  50. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  51. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  52. ↑ Darcy L (August 19, 1972). "Delirium tremens following withdrawal of nitrazepam". Med J Aust. 2 (8): 450. PMID 5086307. 
  53. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  54. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  55. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  56. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  57. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  58. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  59. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  60. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  61. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  62. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  63. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  64. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  65. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  66. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  67. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  68. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  69. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  70. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  71. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  72. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  73. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  74. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  75. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  76. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  77. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  78. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  79. ↑ Kripke, Daniel F (2008). "Evidence That New Hypnotics Cause Cancer" (PDF). Department of Psychiatry, UCSD. University of California. the likelihood of cancer causation is sufficiently strong now that physicians and patients should be warned that hypnotics possibly place patients at higher risk for cancer. 
  80. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  81. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  82. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  83. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  84. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  85. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  86. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  87. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  88. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  89. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  90. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  91. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  92. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  93. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  94. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  95. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  96. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  97. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  98. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  99. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  100. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  101. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  102. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  103. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  104. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  105. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  106. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  107. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  108. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  109. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  110. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  111. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  112. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  113. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  114. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  115. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  116. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  117. ↑ Hoffmann–La Roche. "Mogadon". RxMed. Retrieved 26 May 2009. 
  118. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  119. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  120. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  121. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  122. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  123. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  124. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  125. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  126. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  127. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  128. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  129. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Nitrazepam&oldid=24674"